Ensituximab

Names

[ Name ]:
Ensituximab

Biological Activity

[Description]:

Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer[1][2].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

[In Vitro]

Ensituximab (NPC-1C) 是一种嵌合 IgG1 单克隆抗体，在结合其靶标后促进抗体依赖性细胞的细胞毒性，MUC5AC 是一种肿瘤特异性变体，一种由结直肠癌 (CRC) 和胰腺癌特异性表达的抗原[1]。

[References]

[1]. Richard D Kim, et al. Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. Clin Cancer Res. 2020 Jul 15;26(14):3557-3564.

[2]. Julian A Marin-Acevedo, et al. Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol. 2018 Jan 12;11(1):8.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.